Authors
Susan I Colace, Meenakshi Devidas, Zhiguo Bruce Chen, Robert J Hayashi, Brent L Wood, Natia Esiashvili, Samir Patel, Andrew J Carroll, Nyla A Heerema, Barbara Asselin, Karen R Rabin, Patrick A Zweidler-McKay, Elizabeth A Raetz, Mignon L Loh, Naomi J Winick, William L Carroll, David T Teachey, Stuart S Winter, Kimberly P Dunsmore
Publication date
2023/11/28
Journal
Blood
Volume
142
Pages
517
Publisher
Content Repository Only!
Description
Introduction
Previous clinical trials have reported that adolescent and young adult (AYA) patients treated for T-cell acute lymphoblastic leukemia (T-ALL) have lower disease-free survival (DFS) and overall survival (OS) and increased toxicity as compared to younger patients. Results for the AYA cohort treated on two COG international phase 3 trials for T-ALL are reported here.
Patients and Methods
AALL0434 enrolled 1562 T-ALL patients (2007-2014) and AALL1231 enrolled 615 T-ALL patients (2014-2019) treated on augmented BFM (ABFM) regimens. AYA patients were defined as age ≥16 years of age (AALL0434: n=226; AALL1231: n = 107). Both studies allowed enrollment up to age 31 years.
On AALL0434, participants were randomized to receive escalating dose methotrexate (CMTX) without leucovorin rescue + pegaspargase or high dose MTX (HDMTX) + leucovorin rescue. Intermediate and high-risk …
Total citations
20242
Scholar articles
SI Colace, M Devidas, ZB Chen, RJ Hayashi, BL Wood… - Blood, 2023